Regeneron Pharmaceuticals Inc (REGN)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$10.10 (+1.32%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Regeneron Pharmaceuticals Inc (REGN)
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Key Insights

Critical company metrics and information
  • Share Price

    $778.00
  • Market Cap

    $85.49 Billion
  • Total Outstanding Shares

    108.07 Million Shares
  • Total Employees

    14,176
  • Dividend

    No dividend
  • IPO Date

    April 2, 1991
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.regeneron.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities, Continuing$-2.88 Billion
Net Cash Flow From Operating Activities, Continuing$4.25 Billion
Net Cash Flow From Financing Activities, Continuing$-1.51 Billion
Net Cash Flow$-148.40 Million
Exchange Gains/Losses$200000.00
Net Cash Flow From Financing Activities$-1.51 Billion
Net Cash Flow From Operating Activities$4.25 Billion
Net Cash Flow, Continuing$-148.60 Million
Net Cash Flow From Investing Activities$-2.88 Billion

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Income/Loss Available To Common Stockholders, Basic$4.65 Billion
Costs And Expenses$9.87 Billion
Preferred Stock Dividends And Other Adjustments$0.00
Income/Loss From Continuing Operations Before Tax$4.97 Billion
Other Operating Expenses$2.08 Billion
Income/Loss From Continuing Operations After Tax$4.65 Billion
Research and Development$4.90 Billion
Benefits Costs and Expenses$8.88 Billion
Operating Expenses$9.87 Billion
Net Income/Loss$4.65 Billion
Nonoperating Income/Loss$996.00 Million
Net Income/Loss Attributable To Parent$4.65 Billion
Diluted Average Shares$231.50 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Income Tax Expense/Benefit$314.90 Million
Revenues$13.85 Billion
Basic Average Shares$216.00 Million
Basic Earnings Per Share$43.24
Diluted Earnings Per Share$40.42
Selling, General, and Administrative Expenses$2.90 Billion
Operating Income/Loss$3.97 Billion
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Intangible Assets$1.12 Billion
Liabilities And Equity$37.44 Billion
Current Liabilities$3.66 Billion
Noncurrent Assets$18.11 Billion
Equity$29.33 Billion
Assets$37.44 Billion
Liabilities$8.12 Billion
Noncurrent Liabilities$4.46 Billion
Other Non-current Assets$16.99 Billion
Other Current Liabilities$3.16 Billion
Accounts Payable$497.30 Million
Inventory$3.02 Billion
Equity Attributable To Parent$29.33 Billion
Current Assets$19.33 Billion
Other Current Assets$16.32 Billion
Equity Attributable To Noncontrolling Interest$0.00

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Related Companies

View additional S&P 500 companies similar to Regeneron Pharmaceuticals Inc (REGN)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.